Skip to main content

Research Repository

Advanced Search

Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes

Alam, Mustafa; Kontopantelis, Evangelos; Mamas, Mamas A.; Savinova, Olga V.; Jhaveri, Amit; Siddiqui, Emaad; Jhamnani, Sunny

Authors

Mustafa Alam

Evangelos Kontopantelis

Olga V. Savinova

Amit Jhaveri

Emaad Siddiqui

Sunny Jhamnani



Abstract

Objective
The anti-inflammatory drug colchicine has recently shown benefits in the prevention of major adverse cardiovascular events (MACE) in patients with the acute coronary syndrome (ACS) and chronic coronary syndromes (CCS). This meta-analysis focuses on understanding Colchicine’s effects on the high-sensitivity C-reactive protein (hs-CRP) to provide mechanistic insight to explain its clinical event reduction.

Methods
A computerized search of MEDLINE was conducted to retrieve journal articles with studies performed on humans from 1 January 2005 to 1 January 2022, using keywords: ‘Colchicine AND Coronary’, ‘Colchicine AND CRP’, and ‘Colchicine AND Coronary Artery Disease’. Studies were included if they measured hs-CRP changes from baseline, and colchicine or placebo were given to patients with ACS or CCS.

Results
Thirteen studies with a biomarker subgroup population of 1636 patients were included in the hs-CRP meta-analysis. Of those 13 studies, 8 studies with a total population of 6016 reported clinical events defined as myocardial infarction (MI), stroke, cardiovascular death, periprocedural MI, repeat angina after PCI and repeat revascularization. Multivariate analysis revealed a weak negative correlation of −0.1056 (P = 0.805) between change in CRP and clinical events. Overall, colchicine treatment resulted in a greater reduction in hs-CRP levels compared with placebo (Mean Difference: -1.59; 95% Confidence Interval, −2.40 to −0.79, P = 0.0001) and clinical events (Odds Ratio: 0.78; 95% Confidence Interval 0.64 to 0.95, P = 0.01)

Conclusion
Colchicine therapy is associated with a reduction in hs-CRP and clinical events in patients with ACS and CCS. This finding supports colchicine’s anti-inflammatory efficacy via CRP reduction to explain its clinical benefit.

Citation

Alam, M., Kontopantelis, E., Mamas, M. A., Savinova, O. V., Jhaveri, A., Siddiqui, E., & Jhamnani, S. (2023). Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes. Coronary Artery Disease, 34(3), 210-215. https://doi.org/10.1097/mca.0000000000001220

Journal Article Type Article
Acceptance Date Nov 24, 2022
Online Publication Date Feb 9, 2023
Publication Date 2023-05
Deposit Date Jun 23, 2023
Journal Coronary Artery Disease
Print ISSN 0954-6928
Publisher Lippincott, Williams & Wilkins
Peer Reviewed Peer Reviewed
Volume 34
Issue 3
Pages 210-215
DOI https://doi.org/10.1097/mca.0000000000001220
Keywords Cardiology and Cardiovascular Medicine; General Medicine
Publisher URL https://journals.lww.com/coronary-artery/Abstract/2023/05000/Meta_analysis_of_the_effect_of_colchicine_on.6.aspx